A Phase II Single Center Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor (GM CSF and Ifosfamide Carboplatin Etoposide) For Patients With Relapsed Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma

The purpose of this study is to evaluate safety and efficacy of naxitamab, granulocyte macrophage Colony Stimulating Factor (GM CSF) and Isofosfamide/Carboplatin/Etoposide (NICE) for Patients With Relapsed /Refractory, soft tissue or anti GD2 immunotherapy refractory Neuroblastoma

Start Date20 Aug 2020

Sponsor / Collaborator

Fundació Sant Joan de Déu

100 Clinical Results associated with Granulocyte Macrophage Colony Stimulating Factor(Fundació Sant Joan de Déu)

100 Translational Medicine associated with Granulocyte Macrophage Colony Stimulating Factor(Fundació Sant Joan de Déu)

100 Patents (Medical) associated with Granulocyte Macrophage Colony Stimulating Factor(Fundació Sant Joan de Déu)

Literatures (Medical) associated with Granulocyte Macrophage Colony Stimulating Factor(Fundació Sant Joan de Déu)

01 Jan 2023·Turkish Neurosurgery

Evaluation of the effect of granulocyte–macrophage colony stimulating factor on spinal fusion in a rat model of spinal surgery

Article

Author: Bal, Emre ; Akpolat, Ahmet Onur ; Aksay, Mehmet Fatih ; Kilinc, Bekir Eray

AIMTo evaluate the effects of granulocyte colony stimulating factor (G-CSF) on spinal fusion through manual palpation, radiological examinations, and histopathological analyses in a rat model.MATERIAL AND METHODSA total of 21 rats were evaluated in this study. The rats were divided into the following three groups, each consisting of seven rats: preoperative G-CSF, postoperative G-CSF, and a control group. L4-L5 posterolateral fusion was performed in all three groups. The preoperative G-CSF group received 5 μg/kg G-CSF subcutaneously for 5 days in the preoperative period, while the postoperative G-CSF group received the same intervention in the postoperative period. No additional postoperative procedures were performed in the control group. All rats were euthanized at 6 weeks, and the fusion site was evaluated using manual palpation, radiological examinations, and histopathological analyses.RESULTSAccording to the classification of subjects according to manual examination, preoperative and postoperative G-CSF groups had significantly higher rates of "single prominent callus formation + fusion" (p < 0.05). When direct radiography scores were evaluated, the number of subjects with "unilateral solid new bone density - contralateral nonsolid bone density" was significantly greater in the preoperative G-CSF group, while "bilateral solid new bone densities" was more prevalent in the postoperative G-CSF group (p < 0.05). In regards to histopathological scores, the number of subjects rated as "fibrocartilage tissue is more than bone tissue" was higher in the preoperative G-CSF group, the number of subjects rated as-bone tissue is more than fibrocartilage tissue" was higher in the postoperative G-CSF group, and the number of subjects rated as "fibrous tissue is more than fibrocartilage tissue" was greaterin the control group (p=0.01). Preoperative and postoperative G-CSF groups had significantly higher manual examination, radiological, and histopathological scores and greater volume of new bone formation on 3D CT compared to the control group (p < 0.05).CONCLUSIONThe results of our study demonstrated that preoperative and postoperative administration of G-CSF had positive effects on spinal fusion in a rat model.

15 May 2011·Clinical Cancer ResearchQ1 · MEDICINE

MHC Class I–Presented Tumor Antigens Identified in Ovarian Cancer by Immunoproteomic Analysis Are Targets for T-Cell Responses against Breast and Ovarian Cancer

Q1 · MEDICINE

Article

Author: Morse, Michael A. ; Sinnathamby, Gomathinayagam ; Secord, Angeles A. ; Blackwell, Kimberly ; Hobeika, Amy C. ; Philip, Ramila ; Lyerly, H. Kim ; Philip, Mohan ; Osada, Takuya ; Hafner, Julie ; Clay, Timothy M.

AbstractPurpose: The purpose of this study is to test whether peptide epitopes chosen from among those naturally processed and overpresented within MHC molecules by malignant, but not normal cells, when formulated into cancer vaccines, could activate antitumor T-cell responses in humans.Experimental Design: Mixtures of human leukocyte antigen A2 (HLA-A2)-binding ovarian cancer-associated peptides were used to activate naive T cells to generate antigen-specific T cells that could recognize ovarian and breast cancers in vitro. Combinations of these peptides (0.3 mg of each peptide or 1 mg of each peptide) were formulated into vaccines in conjunction with Montanide ISA-51 and granulocyte monocyte colony stimulating factor which were used to vaccinate patients with ovarian and breast cancer without evidence of clinical disease in parallel pilot clinical trials.Results: T cells specific for individual peptides could be generated in vitro by using mixtures of peptides, and these T cells recognized ovarian and breast cancers but not nonmalignant cells. Patient vaccinations were well tolerated with the exception of local erythema and induration at the injection site. Nine of the 14 vaccinated patients responded immunologically to their vaccine by inducing peptide-specific T-cell responses that were capable of recognizing HLA-matched breast and ovarian cancer cells.Conclusion: Mixtures of specific peptides identified as naturally presented on cancer cells and capable of activating tumor-specific T cells in vitro also initiate or augment immune responses toward solid tumors in cancer patients. Clin Cancer Res; 17(10); 3408–19. ©2011 AACR.

01 May 2011·Clinical & Experimental AllergyQ2 · MEDICINE

Effects of the cyclin‐dependent kinase inhibitor R‐roscovitine on eosinophil survival and clearance

Q2 · MEDICINE

Article

Author: A S Cowburn ; A Gibson ; S N Farrow ; M R Foster ; A Sobolewski ; Lena Uller ; J K Juss ; E R Chilvers ; P Marco-Casanova ; A M Condliffe ; N Farahi ; A J Langton

SummaryBackground Eosinophils are pro‐inflammatory cells implicated in the pathogenesis of asthma and atopy. Apoptosis has been proposed as a potential mechanism underlying the resolution of eosinophilic inflammation and studies have indicated the ability of interventions that induce human eosinophil apoptosis to promote the resolution of eosinophilic inflammation. Recently, the cyclin‐dependent kinase (CDK) inhibitor R‐roscovitine was shown to enhance neutrophil apoptosis and promote the resolution of neutrophilic inflammation.Objective The purpose of this study was to examine the expression of CDKs in human blood eosinophils, the effects of R‐roscovitine on eosinophil survival in vitro and whether R‐roscovitine could influence eosinophilic lung inflammation in vivo.Methods Eosinophils were isolated from human peripheral blood and the effects of R‐roscovitine on apoptosis, degranulation and phagocytic uptake examined in vitro. The effects of R‐roscovitine on eosinophilic lung inflammation in vivo were also assessed using an ovalbumin mouse model.Results Our data demonstrate that human eosinophils express five known targets for R‐roscovitine: CDK1, ‐2, ‐5, ‐7 and ‐9. R‐roscovitine induced eosinophil apoptosis in a time‐ and concentration‐dependent manner but also accelerated transition to secondary necrosis as assessed by microscopy, flow cytometry and caspase activation. In addition, we show that R‐roscovitine can override the anti‐apoptotic signals of GM‐CSF and IL‐5. We report that the pro‐apoptotic effect of R‐roscovitine is associated with suppression of Mcl‐1L expression and that this compound enhanced phagocytic clearance of eosinophils by macrophages. Finally, we show that R‐roscovitine induces apoptosis in murine peripheral blood and spleen‐derived eosinophils; despite this, R‐roscovitine did not modulate the tissue and lumen eosinophilia characteristic of the ovalbumin mouse model of airway eosinophilia.Conclusion and Clinical Relevance These data demonstrate that R‐roscovitine is capable of inducing rapid apoptosis and secondary necrosis in eosinophils but does not affect the onset or improve the resolution of eosinophilic airway inflammation in vivo.Cite this as: N. Farahi, L. Uller, J. K. Juss, A. J. Langton, A. S. Cowburn, A. Gibson, M. R. Foster, S. N. Farrow, P. Marco‐ Casanova, A. Sobolewski, A. M. Condliffe and E. R. Chilvers, Clinical & Experimental Allergy, 2011 (41) 673–687.

100 Deals associated with Granulocyte Macrophage Colony Stimulating Factor(Fundació Sant Joan de Déu)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neuroblastoma recurrent	Phase 2	ES	Fundació Sant Joan de Déu	20 Aug 2020
Refractory Neuroblastoma	Phase 2	ES	Fundació Sant Joan de Déu	20 Aug 2020
Soft Tissue Neoplasms	Phase 2	ES	Fundació Sant Joan de Déu	20 Aug 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Granulocyte Macrophage Colony Stimulating Factor(Fundació Sant Joan de Déu)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation